- TLDR Biotech
- Archive
- Page -5
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | May 1 - 4, 2025
Aviva Capital Partners announces plans for £1B ($1.3B) cancer research and treatment hub in London, Kura Oncology earns $45M milestone payment from Kyowa Kirin for ziftomenib NDA submission in acute leukemias, Amgen executives advocate for tax incentives (not tariffs) to boost US pharmaceutical manufacturing, Pliant Therapeutics cuts 45% of workforce to extend cash ahead of results from halted idiopathic pulmonary fibrosis drug study + 26 more stories
Biotech & Pharma Updates | April 30 - May 1, 2025
Siren Biotechnology tries crowdfunding, Eli Lilly shares drop after CVS removes Zepbound from coverage lists, Samsung Biologics signs $518M contract with US pharma through 2031, Kronos Bio agrees to acquisition by Kevin Tang's Concentra Biosciences for $0.57 per share plus contingent value rights + 37 more stories
Biotech & Pharma Updates | April 29 - 30, 2025
Novartis scoops up Regulus Tx for up to $1.7B, Regeneron's Lynozyfic bispecific lands EU approval for multiple myeloma, Zeon Systems launches with AI-driven robotics for laboratory automation (turning natural language into experimental design) + 30 more stories
Biotech & Pharma Updates | April 28 - 29, 2025
Novo Nordisk and Hims & Hers partner to offer discounted Wegovy through telehealth platform after settling compounding dispute, Abeona Therapeutics' Zevaskyn (a skin cell therapy) received FDA approval for epidermolysis bullosa at $3.1 million list price + 38 more stories
Biotech & Pharma Updates | April 27 - 28, 2025
Merck KGaA to acquire SpringWorks Therapeutics for $3.9bn, Novavax believes its COVID-19 vaccine application is approvable despite FDA request for postmarketing clinical trial commitment, Biohaven $600M strategic investment from Oberland Capital, HSBC downgrades Eli Lilly stock due to high valuation and competition from Novo Nordisk + 31 more stories
Biotech & Pharma Updates | April 24 - 27, 2025
Summit Tx shares plunge after Akeso reveals less-than-stellar overall survival data for Keytruda-challenging bispecific, Pfizer's anti-PD-1 mAb delivers positive Ph3 results in high-risk non-muscle invasive bladder cancer, AbbVie plans $10B US investment over next decade including four new manufacturing facilities, Novavax may need to conduct another clinical trial for its COVID-19 vaccine + 34 more stories
Biotech & Pharma Updates | April 23 - 24, 2025
Granite Bio's $100M launch going after I&I, Sanofi reports strong Q1 earnings, Thermo Fisher joins the US manufacturing rush with $2B commitment, Merck & Co.'s $200M tariff warning, FDA's drug safety databases neglected after sweeping agency layoffs + 29 more stories
Biotech & Pharma Updates | April 22 - 23, 2025
Eli Lilly continues crusade against unauthorized GLP-1 sales, AI-powered ADC developer launches from stealth with $20M, Claris Ventures first closing of targeting $114M Italy-focused biotech fund, Sanofi returns NK cell engager SAR443579 to Innate Pharma, Illumina telegraphs more San Diego layoffs + 20 more stories
Biotech & Pharma Updates | April 21 - 22, 2025
Roche pledges $50B to expand US drug production, AstraZeneca rejoins PhRMA, Biolinq $100M Series C for intradermal biosensors in glucose monitoring, B Cobenfy (xanomeline/trospium chloride), an M1/M4 muscarinic receptor agonist, failed Ph3 trial as add-on therapy for schizophrenia.
Biotech & Pharma Updates | April 18 - 21, 2025
Novo Nordisk submits oral GLP-1 approval application to FDA, Alis Biosciences launches fund to unlock trapped capital from public biotech companies with depressed valuations, Tempest Therapeutics lays off 80% of staff following strategic alternatives announcement + more NIH and federal funding chaos
Biotech & Pharma Updates | April 15 - 16, 2025
Ayrmid misses upped bluebird bio offer deadline, Glycomine raises $115M Series C to develop treatment for rare disease PMM2-congenital disorder of glycosylation, Dutch cabinet envisions Netherlands as global biotech leader by 2040 - investing €1.3 billion ($1.48 billion) to accelerate innovations to market, EU and US pharma companies demand EC support in facing US tariffs, CDC struggles to respond to Texas measles outbreak + 31 more stories